Interestingly, in a phase 2A study (NCT03256526), liver-specific KHK inhibition significantly reduced whole liver fat and inflammatory markers, suggesting a potential clinical benefit in the treatment of NASH.218. This evidence concerns the gene KHK and metabolic dysfunction-associated steatohepatitis.